SCHEMBL390340

SCHEMBL390340

COc1ccnc(N2CCN(C(=O)OCC(C)(C)C)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.54
NOS1 P29475 2/20 0.50
NOS2 P35228 2/20 0.50
NOS3 P29474 1/20 0.50
HPGD P15428 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HSD17B10 Q99714 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GRM5 P41594 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
OPRD1 P41143 1/20 0.42
KCNH2 Q12809 1/20 0.42
LMNA P02545 1/20 0.42
IDE P14735 1/20 0.42
HIF1A Q16665 1/20 0.42
SMO Q99835 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390651 0.86 NOS1 (0.49) NOS1NOS2NOS3HPGDNPSR1
SCHEMBL390540 0.85 OPRD1 (0.57) HRH3NOS1NOS2HPGDSMN1; SMN2
SCHEMBL30546118 0.84 HRH3 (0.57) HRH3SMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL5682996 0.84 HRH3 (0.57) HRH3SMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL390338 0.84 HRH3 (0.56) HRH3HPGDL3MBTL1SMN1; SMN2KDM4E
SCHEMBL390619 0.84 HRH3 (0.56) HRH3NOS1NOS2HPGDGRM5
SCHEMBL388016 0.83 HRH3 (0.57) HRH3HPGDSMN1; SMN2ALDH1A1KDM4E
SCHEMBL10167993 0.83 HPGD (0.42) HRH3NOS1NOS2NOS3HPGD
SCHEMBL387328 0.82 GRIN2D (0.47) HRH3NOS1NOS2NOS3HPGD
SCHEMBL389756 0.82 HRH3 (0.56) HRH3HPGDGRM5SMN1; SMN2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US claimed
EP-1870401-A1 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-12-26 EP claimed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
EP-1870401-A1 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062293-A1 1,4-Substituted Piperazine Derivatives GRIN1, GRM1, GRIN2C HRH3 661/4885NOS1 884/4885NOS2 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.